Abstract
Background: Epidermal Growth Factor Receptor (EGFR) is overexpressed in a variety of cancers and is associated with poor prognosis, low survival rate, and resistance of cancer cells to treatment.
Objective: This review discusses the combined effect of EGFR inhibitor and radiation therapy in cancer treatment.
Method: The recent literature and patent applications were considered in which the role of EGFR in cancer and EGFR inhibitors, as well as the preclinical and clinical studies are related to synergistic effects of EGFR inhibitors and ionizing radiation in the treatment of various cancers.
Results: The specific inhibition has been introduced as targeted therapy for treatment of cancers. Two major pharmacological approaches for inhibition of EGFR are monoclonal antibodies and smallmolecule tyrosine kinase inhibitors. The use of these agents in combination with ionizing radiation results in increasing the cytotoxicity on tumors that are rich in expression of EGFR.
Conclusion: The combination of EGFR inhibitor and ionizing radiation has synergistic effect and resulted in improvement of radiotherapy in patients.
Keywords: Cancer, EGFR, monoclonal antibodies, radiation therapy, sensitizing, tyrosine kinase inhibitors.
Recent Patents on Anti-Cancer Drug Discovery
Title:Synergistic Effect of Epidermal Growth Factor Receptor Inhibitors and Ionization Radiation in Cancer Treatment
Volume: 12 Issue: 4
Author(s): Zahra Shaghaghi and Seyed Jalal Hosseinimehr*
Affiliation:
- Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari,Iran
Keywords: Cancer, EGFR, monoclonal antibodies, radiation therapy, sensitizing, tyrosine kinase inhibitors.
Abstract: Background: Epidermal Growth Factor Receptor (EGFR) is overexpressed in a variety of cancers and is associated with poor prognosis, low survival rate, and resistance of cancer cells to treatment.
Objective: This review discusses the combined effect of EGFR inhibitor and radiation therapy in cancer treatment.
Method: The recent literature and patent applications were considered in which the role of EGFR in cancer and EGFR inhibitors, as well as the preclinical and clinical studies are related to synergistic effects of EGFR inhibitors and ionizing radiation in the treatment of various cancers.
Results: The specific inhibition has been introduced as targeted therapy for treatment of cancers. Two major pharmacological approaches for inhibition of EGFR are monoclonal antibodies and smallmolecule tyrosine kinase inhibitors. The use of these agents in combination with ionizing radiation results in increasing the cytotoxicity on tumors that are rich in expression of EGFR.
Conclusion: The combination of EGFR inhibitor and ionizing radiation has synergistic effect and resulted in improvement of radiotherapy in patients.
Export Options
About this article
Cite this article as:
Shaghaghi Zahra and Hosseinimehr Jalal Seyed*, Synergistic Effect of Epidermal Growth Factor Receptor Inhibitors and Ionization Radiation in Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery 2017; 12 (4) . https://dx.doi.org/10.2174/1574892812666170829150057
DOI https://dx.doi.org/10.2174/1574892812666170829150057 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenomics: Dont Forget the Children
Current Pharmacogenomics and Personalized Medicine Stress Signaling from Irradiated to Non-Irradiated Cells
Current Cancer Drug Targets Novel Systemic Cardiovascular Disease Biomarkers
Current Molecular Medicine Enzyme-Instructed Self-assembly in Biological Milieu for Theranostics Purpose
Current Medicinal Chemistry Carbon Monoxide-Releasing Molecules: A Pharmacological Expedient to Counteract Inflammation
Current Pharmaceutical Design Personalized Medicine and Molecular Diagnostics for Obesity: Metabolic Systems Reconstruction and Gut Microbiome Biomarkers
Current Pharmacogenomics and Personalized Medicine OMICS-Derived Targets for Inflammatory Gut Disorders: Opportunities for the Development of Nutrition Related Biomarkers
Endocrine, Metabolic & Immune Disorders - Drug Targets The Heat Shock Connection of Metabolic Stress and Dietary Restriction
Current Pharmaceutical Biotechnology Roles of Fluorine in Drug Design and Drug Action
Letters in Drug Design & Discovery Anticancer Agents Based on Vulnerable Components in a Signalling Pathway
Mini-Reviews in Medicinal Chemistry Advances in the Chemistry and Pharmacology of Ecteinascidins, A Promising New Class of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Synthesis and Biological Evaluation of Quinazoline Derivatives as Potential Anticancer Agents (II)
Anti-Cancer Agents in Medicinal Chemistry Interactions between Transporters and Herbal Medicines/Drugs: A Focus on Hepatoprotective Compounds
Current Drug Metabolism Meta-analysis Reveals No Association of DNMT3B -149 C>T Gene Polymorphism With Overall Cancer Risk
Current Genomics Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Current Cancer Drug Targets Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
CNS & Neurological Disorders - Drug Targets Phytochemicals: Key to Effective Anticancer Drugs
Mini-Reviews in Organic Chemistry A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents
Current Pharmaceutical Design Labelling and Tracking of Human Mesenchymal Stromal Cells in Preclinical Studies and Large Animal Models of Degenerative Diseases
Current Stem Cell Research & Therapy Anti-Inflammatory and Anti-Oxidant Activity of a New Class of Phenyl- Pyrazolone Derivatives
Current Drug Discovery Technologies